LBHD1: A Protein Involved in Cellular Processes and Therapeutic Effects

Target Name: LBHD1

NCBI ID: G79081

LBHD1

LBHD1: A Protein Involved in Cellular Processes and Therapeutic Effects

LBHD1 (LBH domain-containing protein 1) is a protein that is expressed in various tissues and cells in the human body. It is a member of the BTK (Bruton-Tierney) gene family, which is involved in the development and maintenance of blood cells. LBHD1 is also known as P092G2, and it is localized to the endoplasmic reticulum (ER) and the cytoplasm of various cell types.

The P092G2 gene was identified in the human genome project, and it has been shown to encode a protein that is involved in a variety of cellular processes. One of the most interesting functions of LBHD1 is its role in the regulation of cell-cell adhesion, as well as its role in the development and maintenance of various tissues and organs.

In addition to its role in cell-cell adhesion, LBHD1 is also involved in the regulation of cell signaling pathways, as well as the development and maintenance of the nervous system. It is a known participant in the PI3K/Akt signaling pathway, which is involved in the regulation of cellular processes such as cell growth, differentiation, and survival.

Furthermore, LBHD1 is also involved in the regulation of the cytoskeleton, which is the structure that gives cells their shape and stability. It is a known participant in the Microtubule-protein subfamily, which is involved in the regulation of cell division and differentiation.

In addition to its role in the regulation of cell signaling pathways and the cytoskeleton, LBHD1 is also involved in the regulation of cell death. It is a known participant in the caspase-3 signaling pathway, which is involved in the regulation of cell death.

Due to its involvement in a variety of cellular processes, LBHD1 has been shown to be a potential drug target or biomarker. For example, studies have shown that inhibiting the activity of LBHD1 has been shown to have therapeutic effects in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In addition to its potential therapeutic effects, LBHD1 has also been shown to be a potential biomarker for a variety of diseases. For example, studies have shown that levels of LBHD1 have been increased in a variety of cancer tissues, and that inhibiting the activity of LBHD1 has been shown to have therapeutic effects in a variety of cancer types.

Overall, LBHD1 is a protein that is involved in a variety of cellular processes and has been shown to have therapeutic effects in a variety of diseases. As a result, it is a potential drug target or biomarker for a variety of medical conditions. Further research is needed to fully understand the role of LBHD1 in cellular processes and its potential as a therapeutic agent.

Protein Name: LBH Domain Containing 1

The "LBHD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LBHD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets